Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus KLEBCIL.
CLOXAPEN vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic